Scientists / Our Scientists

Brad Friedman

Distinguished Scientist, Bioinformatics and Computational Biology, Computational Sciences

Postdoc Mentor

"Genomics brings new insights to neurodegenerative disease."

Years at Genentech

Publications at Genentech

Awards & Honors

I joined Genentech in 2011 and led the development of software infrastructure which continues to underlie much of our company’s gene expression research. In 2014 I began collaborating with the Neuroscience department to study the role of non-neuronal cells (“glia”) in neurodegenerative diseases, with a particular emphasis on Alzheimer’s and Parkinson’s diseases. We combine human genetics, gene expression and other types of data to identify and understand novel therapeutic targets and biomarkers.

At Genentech I have access to both industry-leading databases and information systems as well as world-class neuroscientists with whom I collaborate to develop and test hypotheses emerging from these data. This highly collaborative research environment is an exciting place to do science.

Featured Publication

Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer0s Disease Not Evident in Mouse Models.

Cell Rep. 2018 Jan 16;22(3):832-847.

Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV.

View Abstract

Human genetics and neuropathology point to a role for glial cells in the development of Alzheimer’s and other neurodegenerative diseases. Microglia in particular are thought to have both “good” aspects, such phagocytosis of lipids, protein aggregates and apoptotic cells, and “bad” aspects, such as secretion of toxic inflammatory factors, actively spreading prion-like protein species, or aberrant engulfment of not-yet-dead synapses or neurons. I combine human genetics and gene expression to understand which of these pathways are most important for disease progression, and which might be amenable to therapeutic intervention.

Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis

Journal of Neuroscience, ISSN: 02706474

Ainhoa Etxeberria; Yun-An A. Shen; Stephen T. Vito; Sean M. Silverman; Jose Imperio; Guita Lalehzadeh; Allison L. Soung; Du; Luke Xie; Man Kin Choy; Yi-Chun Hsiao; Hai Ngu; Chang Hoon Cho; Soumitra Ghosh; Gloriia Novikova; Mitchell G. Rezzonico; Rebecca Leahey; Martin Weber; Alvin Gogineni; Justin Elstrott; Monica Xiong; Jacob J. Greene; Kimberly L. Stark; Pamela Chan; Gillie A. Roth; Max Adrian; Qingling Li; Meena Choi; Weng Ruh Wong; Wendy N. Sandoval; Oded Foreman; Alicia A. Nugent; Brad A. Friedman; Shraddha Sadekar; Isidro Hötzel; David V. Hansen; Ben Chih; Tracy J. Yuen; Robby M. Weimer; Amy Easton; William J. Meilandt; Christopher J. Bohlen

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Brad Friedman

Distinguished Scientist, Bioinformatics and Computational Biology, Computational Sciences

Featured Publication

Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer0s Disease Not Evident in Mouse Models.